Edimer raises $18m to develop ultra-rare disease therapy
This article was originally published in Scrip
Executive Summary
Biotechnology firm Edimer Pharmaceuticals has raised $18m in series B financing –with input from Sanofi-Genzyme venture capital firm – to continue development of its novel therapy treating rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED).